595 related articles for article (PubMed ID: 25850950)
1. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
Katz SC; Burga RA; McCormack E; Wang LJ; Mooring W; Point GR; Khare PD; Thorn M; Ma Q; Stainken BF; Assanah EO; Davies R; Espat NJ; Junghans RP
Clin Cancer Res; 2015 Jul; 21(14):3149-59. PubMed ID: 25850950
[TBL] [Abstract][Full Text] [Related]
2. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA
Katz SC; Hardaway J; Prince E; Guha P; Cunetta M; Moody A; Wang LJ; Armenio V; Espat NJ; Junghans RP
Cancer Gene Ther; 2020 May; 27(5):341-355. PubMed ID: 31155611
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.
Saied A; Licata L; Burga RA; Thorn M; McCormack E; Stainken BF; Assanah EO; Khare PD; Davies R; Espat NJ; Junghans RP; Katz SC
Cancer Gene Ther; 2014 Nov; 21(11):457-62. PubMed ID: 25277132
[TBL] [Abstract][Full Text] [Related]
4. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
[TBL] [Abstract][Full Text] [Related]
5. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.
Katz SC; Moody AE; Guha P; Hardaway JC; Prince E; LaPorte J; Stancu M; Slansky JE; Jordan KR; Schulick RD; Knight R; Saied A; Armenio V; Junghans RP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843493
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response.
Junghans RP; Ma Q; Rathore R; Gomes EM; Bais AJ; Lo AS; Abedi M; Davies RA; Cabral HJ; Al-Homsi AS; Cohen SI
Prostate; 2016 Oct; 76(14):1257-70. PubMed ID: 27324746
[TBL] [Abstract][Full Text] [Related]
7. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.
Burga RA; Thorn M; Point GR; Guha P; Nguyen CT; Licata LA; DeMatteo RP; Ayala A; Joseph Espat N; Junghans RP; Katz SC
Cancer Immunol Immunother; 2015 Jul; 64(7):817-29. PubMed ID: 25850344
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.
Cahan B; Leong L; Wagman L; Yamauchi D; Shibata S; Wilzcynski S; Williams LE; Yazaki P; Colcher D; Frankel P; Wu A; Raubitschek A; Shively J; Wong JYC
Cancer Biother Radiopharm; 2017 Sep; 32(7):258-265. PubMed ID: 28910150
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
11. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
12. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
Ahmed N; Brawley V; Hegde M; Bielamowicz K; Kalra M; Landi D; Robertson C; Gray TL; Diouf O; Wakefield A; Ghazi A; Gerken C; Yi Z; Ashoori A; Wu MF; Liu H; Rooney C; Dotti G; Gee A; Su J; Kew Y; Baskin D; Zhang YJ; New P; Grilley B; Stojakovic M; Hicks J; Powell SZ; Brenner MK; Heslop HE; Grossman R; Wels WS; Gottschalk S
JAMA Oncol; 2017 Aug; 3(8):1094-1101. PubMed ID: 28426845
[TBL] [Abstract][Full Text] [Related]
13. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege KM; Bergsland EK; Fisher GA; Nemunaitis JJ; Warren RS; McArthur JG; Lin AA; Schlom J; June CH; Sherwin SA
J Immunother Cancer; 2017; 5():22. PubMed ID: 28344808
[TBL] [Abstract][Full Text] [Related]
14. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy.
Wieners G; Pech M; Hildebrandt B; Peters N; Nicolaou A; Mohnike K; Seidensticker M; Sawicki M; Wust P; Ricke J
Cardiovasc Intervent Radiol; 2009 Sep; 32(5):937-45. PubMed ID: 19472000
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.
Lopez E; Hidalgo S; Roa E; Gómez J; Hermansen Truan C; Sanders E; Carrasco C; Pacheco R; Salazar-Onfray F; Varas-Godoy M; Borgna V; Lladser A
Oncoimmunology; 2023; 12(1):2225291. PubMed ID: 37363103
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
20. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
